Clot-Buster shows promise for eye stroke in landmark trial
NCT ID NCT04526951
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This Phase 3 trial tested whether the clot-busting drug tenecteplase could improve vision in people with a central retinal artery occlusion (eye stroke). 81 participants received either tenecteplase or aspirin within 4.5 hours of symptoms. The main goal was to see if more patients in the tenecteplase group had significant vision improvement at 30 days.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tenecteplase (a clot-busting drug)
What this could lead to
If it works, this could provide a proven treatment to restore vision in people who have an 'eye stroke' (blocked artery in the eye).
What could go wrong
This is a small, completed Phase 3 trial (81 people). The drug carries a risk of bleeding, and results may not apply to all patients or be confirmed in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL RETINAL ARTERY OCCLUSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aarhus University Hospital
Aarhus, Denmark
-
Bispebjerg University Hospital
Copenhagen, Denmark
-
Haukeland University Hospital
Bergen, Norway
-
Helse Nord Trøndelag Trust
Namsos, Norway
-
Helsinki University Hospital
Helsinki, Finland
-
Karolinska University Hospital
Stockholm, Sweden
-
Kauno Klinikos Kaunas
Kaunas, Lithuania
-
Oslo University Hospital
Oslo, 0424, Norway
-
Rigshospitalet University Hospital
Copenhagen, Denmark
-
St Olav University Hospital
Trondheim, Norway
-
Telemark Hospital Trust
Skien, Norway
-
Turku University Hospital
Turku, Finland
-
University Hospital Antwerp
Antwerp, Belgium
-
University Hospital Leuven
Leuven, 3000, Belgium
-
Vestfold Hospital Trust
Tønsberg, Norway
-
Vestre Viken Hospital Trust Drammen
Drammen, Norway
-
Vilnius University Hospital
Vilnius, Lithuania
-
Østfold Hospital Trust Kalnes, Dept of Ophthalmology
Grålum, Norway